- Home
- BLRX vs CCEL Comparison
BLRX vs CCEL Comparison
Compare BLRX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- CCEL
- Stock Information
- Founded
- BLRX 2003
- CCEL 1989
- Country
- BLRX Israel
- CCEL United States
- Employees
- BLRX N/A
- CCEL N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- BLRX Health Care
- CCEL Health Care
- Exchange
- BLRX Nasdaq
- CCEL Nasdaq
- Market Cap
- BLRX 54.1M
- CCEL 53.9M
- IPO Year
- BLRX 2011
- CCEL 1997
- Fundamental
- Price
- BLRX $0.50
- CCEL $6.34
- Analyst Decision
- BLRX Strong Buy
- CCEL
- Analyst Count
- BLRX 2
- CCEL 0
- Target Price
- BLRX $11.50
- CCEL N/A
- AVG Volume (30 Days)
- BLRX 253.7K
- CCEL 3.4K
- Earning Date
- BLRX 11-18-2024
- CCEL 10-18-2024
- Dividend Yield
- BLRX N/A
- CCEL N/A
- EPS Growth
- BLRX N/A
- CCEL N/A
- EPS
- BLRX N/A
- CCEL N/A
- Revenue
- BLRX $17,048,000.00
- CCEL $31,641,636.00
- Revenue This Year
- BLRX N/A
- CCEL $3.70
- Revenue Next Year
- BLRX N/A
- CCEL $10.57
- P/E Ratio
- BLRX N/A
- CCEL N/A
- Revenue Growth
- BLRX N/A
- CCEL 1.93
- 52 Week Low
- BLRX $0.44
- CCEL $3.67
- 52 Week High
- BLRX $1.93
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- BLRX 31.82
- CCEL 47.46
- Support Level
- BLRX $0.44
- CCEL $6.16
- Resistance Level
- BLRX $0.56
- CCEL $7.19
- Average True Range (ATR)
- BLRX 0.05
- CCEL 0.30
- MACD
- BLRX -0.01
- CCEL 0.02
- Stochastic Oscillator
- BLRX 23.39
- CCEL 19.53
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.